subject: Aarkstore Enterprise -The Genitourinary Market Outlook to 2015: Competitive landscape, global marke [print this page] The Genitourinary Market Outlook to 2015: Competitive landscape, global market analysis and pipeline analysis
The genitourinary market outlook segments the market into sex hormones, urologicals, genitourinary anti-infectives and other gynaecologicals. For each segment, leading products, developments and market forecasts are presented.The genitourinary market outlook segments the market into sex hormones, urologicals, genitourinary anti-infectives and other gynaecologicals. For each segment, leading products, developments and market forecasts are presented.
Hormonal contraceptives are witnessing maximum clinical development with promising new drugs which the report examines in detail. This report includes detailed competitive analysis of the marketed products, pipeline and major players. Furthermore, the report gives an insight into the key drivers and resistors that will influence the market.
Features and Benefits
Gain a strategic insight into the key drivers and resistors of the market and understand the leading product developments.
Compare the franchises of top players in the genitourinary market across major indications, and assess the current competitive positioning.
Gain up-to-date competitive intelligence across the genitourinary portfolio and understand the major issues affecting the market.
Understand recent events and how they impact the performance of major products and the challenges confronted by leading players.
Forecast sales of the major marketed products as well as key pipeline products in the genitourinary category over the period 2009-15.
Highlights from this report
The global genitourinary market registered sales of $34.6bn in 2009 with growth of 4.1% on 2008. The US remained the largest market in the genitourinary segment, accounting for 46.5% market share. Japan, the second largest regional market with 5.8% share, was the fastest growing in 2009 due to new drug approvals.
Sex hormones remained the largest drug class in 2009 posting sales of $16.2bn and accounting for a 46.9% segment share in the genitourinary market. The class recorded flat growth owing to increasing generic presence and absence of new drug launches.
Urologicals represented the second largest drug class with sales of $14.5bn and a market share of 41.9% in 2009. The segment is expected to demonstrate slow growth in the near to mid-term future as the high sales of Vesicare will be offset by patent expiry of blockbuster products and Alna.
Your key questions answered
What will be the effect of the looming patent expiries of blockbuster products and increased generic erosion on the genitourinary market?
What will be the major growth indications and the accompanying growth drivers in the genitourinary market over the period 200915?
How will the recently launched products affect the genitourinary market performance from 2009-15?
How will the recently launched products affect the genitourinary market performance from 2009-15?
Which companies are best positioned to succeed in the global genitourinary market over the period 200915?
